Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31203
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerez, Antonio-
dc.contributor.authorCarrasco-Sánchez, Francisco Javier-
dc.contributor.authorGonzález, Carlos-
dc.contributor.authorSeguí-Ripoll, José Miguel-
dc.contributor.authorTrescolí, Carlos-
dc.contributor.authorEna, Javier-
dc.contributor.authorBorrell, Mireia-
dc.contributor.authorGomez Huelgas, Ricardo-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-07T10:11:09Z-
dc.date.available2024-02-07T10:11:09Z-
dc.date.created2020-07-18-
dc.identifier.citationBMJ Open Diabetes Research & Care. 2020 Sep;8(1):e001518.es_ES
dc.identifier.issn2052-4897-
dc.identifier.urihttps://hdl.handle.net/11000/31203-
dc.description.abstractIntroduction: This study assessed the efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in insufficiently controlled people with type 2 diabetes. Research design and methods: COBALTA (for its acronym in Spanish, COntrol Basal durante la hospitalizacion y al ALTA) was a multicenter, open-label, single-arm, phase IV trial including 112 evaluable inpatients with type 2 diabetes insufficiently controlled (glycosylated hemoglobin (HbA1c) 8%-10%) with basal insulin and/or non-insulin antidiabetic drugs. Patients were treated with a basal-bolus-correction insulin regimen with Gla-300 during the hospitalization and with Gla-300 and/or non-insulin antidiabetics for 6 months after discharge. The primary endpoint was the HbA1c change from baseline to month 6 postdischarge. Results: HbA1c levels decreased from 8.8%±0.6% at baseline to 7.2%±1.1% at month 6 postdischarge (p<0.001, mean change 1.6%±1.1%). All 7-point blood glucose levels decreased from baseline to 24 hours predischarge (p≤0.001, mean changes from 25.1±66.6 to 63.0±85.4 mg/dL). Fasting plasma glucose also decreased from baseline to 24 hours predischarge (p<0.001), month 3 (p<0.001) and month 6 (p<0.001) postdischarge (mean changes 51.5±90.9, 68.2±96.0 and 77.6±86.4 mg/dL, respectively). Satisfaction was high and hyperglycemia/hypoglycemia perception was low according to the Diabetes Treatment Satisfaction Questionnaire at month 6 postdischarge. The incidence of confirmed (glucose<70 mg/dL)/severe hypoglycemia was 25.0% during hospitalization and 59.1% 6 months after discharge. No safety concerns were reported. Conclusions: Inpatient and intensification therapy at discharge with Gla-300 improved significantly glycemic control of patients with type 2 diabetes insufficiently controlled with other basal insulin and/or non-insulin antidiabetic medication, with high treatment satisfaction. Gla-300 could therefore be a treatment choice for hospital and postdischarge diabetes management.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent10es_ES
dc.language.isoenges_ES
dc.publisherBMJes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectblood Glucosees_ES
dc.subjectdiabetes mellituses_ES
dc.subjecthypoglycemiaes_ES
dc.subjecthypoglycemiaes_ES
dc.subjecttype 2es_ES
dc.titleEfficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1136/bmjdrc-2020-001518es_ES
Appears in Collections:
Artículos Medicina Clínica


Thumbnail

View/Open:
 Efficacy and safety of insulin glargine 300 UmL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2.pdf

577,91 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???